The Top 5 Biosimilar Articles for the Week of July 14

Number 5: Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more convenient subcutaneous option.

Number 4: Inpatient biosimilar use is expanding, especially in oncology and supportive care, presenting significant cost-saving opportunities for health systems while maintaining patient care quality.

Number 3: A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.

Number 2: Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.

Number 1: The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and bone-related metastases.

To read all of these articles and more, visit centerforbiosimilars.com.